SEATTLE, WA, USA I March 21, 2025 I Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating ...
The complement system is a critical part of innate immunity ... Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback